The synthetic peptide T-20 (enfuvirtide, EFV) represents the first compound approved by the FDA known as entry inhibitors (EIs). The resistance mutations associated with this new class of antiretroviral drug are located in the first heptad repeat (HR1) region of gp41. Amino acid changes in codons G36D/S, I37V, V38A/M/E, Q39H/R, Q40H, N42T, and N43D can confer resistance to EFV. In this work we investigated the presence of resistance mutations that occur in patients never treated with EFV and failing HAART with protease inhibitors (PIs), nucleoside reverse transcriptase (RT) inhibitors (NRTIs), and nonnucleoside RT inhibitors (NNRTIs). This knowledge can reveal whether this salvage therapy can be effective in patients failing HAART. For this, we amplified 65 samples from plasma isolates and than sequenced a fragment of 416 nt encompassing the HR1 and HR2 regions (amino acids 33-170 of gp41). The subtype distribution among the 65 isolates was 45 (69.23%) subtype B, 9 (13.85%) subtype C, 7 (10.77%) subtype F1, and 4 (6.15%) mosaics B/F1, B/C, F1/C, and C/F1/B. We found a high prevalence (7.6%) of EFV-associated mutation G36D in this cohort of patients failing HAART therapy, five isolates from subtype B (11.11% within this group). In contrast, when 1079 sequences from drug-naive patients were analyzed, only one showed the G36D substitution. This finding indicates a strong association between the selected position G36D and HAART therapy (p < 0.0001). The isolates that possess these mutations can develop resistance to EFV more rapidly. Nevertheless, more information about the impact of these mutations in salvage therapy with EFV in patients failing HAART must still be obtained.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/aid.2008.0160 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of integrase strand transfer inhibitor resistance in people living with HIV and virological failure.
J Chin Med Assoc
November 2024
Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
Article Synopsis
- This study investigates the resistance profiles of integrase strand transfer inhibitors (INSTIs) in patients from southern Taiwan who experienced failure in antiretroviral therapy (ART), particularly focusing on those previously treated with highly active ART (HAART).
- It analyzes data from patients who failed an INSTI-containing regimen between 2009 and 2022, with genotypic drug resistance tested against established guidelines, revealing insights into mutations associated with treatment failure.
- Among 21 patients who failed INSTI therapy, 40% showed INSTI drug resistance, with specific mutations identified, highlighting the challenges in treating individuals with resistant strains in a treatment-experienced population.
HIV-1 Vpu induces neurotoxicity by promoting Caspase 3-dependent cleavage of TDP-43.
EMBO Rep
October 2024
Institute of Virology and AIDS Research, First Hospital, Jilin University, 130021, Changchun, Jilin, China.
Despite the efficacy of highly active antiretroviral therapy in controlling the incidence and mortality of AIDS, effective interventions for HIV-1-induced neurological damage and cognitive impairment remain elusive. In this study, we found that HIV-1 infection can induce proteolytic cleavage and aberrant aggregation of TAR DNA-binding protein 43 (TDP-43), a pathological protein associated with various severe neurological disorders. The HIV-1 accessory protein Vpu was found to be responsible for the cleavage of TDP-43, as ectopic expression of Vpu alone was sufficient to induce TDP-43 cleavage, whereas HIV-1 lacking Vpu failed to cleave TDP-43.
View Article and Find Full Text PDFVirological impact of HIV drug-resistance testing in children, adolescents, and adults failing first-line ART in Tanzania.
J Glob Antimicrob Resist
December 2024
German Leprosy and Tuberculosis Relief Association (DAHW), Würzburg, Germany; Medmissio, Würzburg, Germany.
Background: Prospective data on the effectiveness of resistance testing in informing treatment decisions and outcomes in with first-line failure in these settings is limited. This study aimed to assess the virological impact of HIV drug-resistance testing in patients with virological failure in Tanzania.
Methods: Participants were randomly assigned to either the control or the experimental group.
Transcription of HIV-1 at sites of intact latent provirus integration.
J Exp Med
September 2024
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
HIV-1 antiretroviral therapy is highly effective but fails to eliminate a reservoir of latent proviruses, leading to a requirement for life-long treatment. How the site of integration of authentic intact latent proviruses might impact their own or neighboring gene expression or reservoir dynamics is poorly understood. Here, we report on proviral and neighboring gene transcription at sites of intact latent HIV-1 integration in cultured T cells obtained directly from people living with HIV, as well as engineered primary T cells and cell lines.
View Article and Find Full Text PDFA multidisciplinary approach for people with HIV failing antiretroviral therapy in South Africa.
South Afr J HIV Med
July 2024
KwaZulu-Natal Department of Health, Northdale Hospital, Pietermaritzburg, South Africa.
Background: South Africa (SA) has the largest antiretroviral therapy (ART) programme worldwide. Multiple factors contribute to virological failure (VF), including poor adherence and viral resistance mutations. A multidisciplinary team (MDT) clinic dedicated to those with VF may be of benefit; however, very little data from SA exist.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!